# A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

Source: https://onco.cc/trials/nct06679829/  
OnCo record `nct06679829` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Siltuximab and Melphalan in Multiple myeloma, run by Memorial Sloan Kettering Cancer Center, now recruiting.

## Summary

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant is a phase 2 interventional study registered as NCT06679829 by Memorial Sloan Kettering Cancer Center, with 215 participants planned, started 2024-11-06 and due to reach its primary completion in 2027-11. Interventions recorded: Siltuximab, Melphalan. Conditions recorded: Multiple Myeloma.

Linked to the drug Siltuximab because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06679829
- Phase: 2
- Setting: Phase II Randomized Trial of Population PK Dosed Melphalan With Interleukin-6 Blockade With Siltuximab Vesrus BSA Based Melphalan in Patients With Multiple Myeloma Over Age 60 Undergoing Autologous Stem Cell Transplantation
- Sponsor: Memorial Sloan Kettering Cancer Center
- Enrolled: 215

## Sources

- ClinicalTrials.gov NCT06679829: https://clinicaltrials.gov/study/NCT06679829

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Melphalan (including hepatic delivery system)](https://onco.cc/drugs/melphalan/), [Siltuximab](https://onco.cc/drugs/siltuximab/)

---
JSON: https://onco.cc/api/v1/entities/nct06679829.json